Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lyell Immunopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Lyell Immunopharma, Inc.’s stock price such as:

• Lyell Immunopharma, Inc.’s current stock price and volume
• Why Lyell Immunopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for LYEL from analysts
• LYEL’s stock price momentum as measured by its relative strength

About Lyell Immunopharma, Inc. (LYEL)

Before we jump into Lyell Immunopharma, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Want to learn more about Lyell Immunopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Lyell Immunopharma, Inc.’s stock price was $14.370.

Lyell Immunopharma, Inc. is up 0.35% from its previous closing price of $14.320.

During the last market session, Lyell Immunopharma, Inc.’s stock traded between $13.920 and $14.680. Currently, there are approximately 23.36 million shares outstanding for Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lyell Immunopharma, Inc. Stock Price History

Lyell Immunopharma, Inc.’s (LYEL) price is currently up 0.35% so far this month.

During the month of September, Lyell Immunopharma, Inc.’s stock price has reached a high of $15.140 and a low of $13.920.

Over the last year, Lyell Immunopharma, Inc. has hit prices as high as $45.000 and as low as $11.470. Year to date, Lyell Immunopharma, Inc.’s stock is down 53.31%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lyell Immunopharma, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were 0 analysts who downgraded Lyell Immunopharma, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Lyell Immunopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lyell Immunopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lyell Immunopharma, Inc. (LYEL) by visiting AAII Stock Evaluator.

Relative Price Strength of Lyell Immunopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Lyell Immunopharma, Inc. has a weighted four-quarter relative price strength of 13.52%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Lyell Immunopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lyell Immunopharma, Inc. Stock Price: Bottom Line

As of September 4, 2026, Lyell Immunopharma, Inc.’s stock price is $14.370, which is up 0.35% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lyell Immunopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.